Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Acute Myeloid Leukemia — Treatment

First-line Second-line SECOND-LINE Acute myeloid leukemia (AML) APL (PML::RARA) Fit — intensive induction Unfit — lower-intensity Post-remission / relapsed Non-high-risk ATRA + arsenic trioxide APL0406 ↗ High-risk ATRA + ATO ± chemo WBC > 10k FLT3 7+3 + midostaurin RATIFY ↗ CD33 7+3 + gemtuzumab ALFA-0701 ↗ sAML CPX-351 Vyxeos ↗ Standard Azacitidine + venetoclax VIALE-A ↗ IDH1 Ivosidenib ± azacitidine AGILE ↗ IDH2 Enasidenib IDH2-mutated ↗ Curative Allogeneic transplant intermediate / adverse risk Maintenance Oral azacitidine QUAZAR ↗ FLT3 Gilteritinib ADMIRAL ↗